It’s known that Neuroendocrine Cancer is quite different in many ways from other cancers, notwithstanding the misnomer term carcinoid which is thankfully being slowly moved out of terminology. As a few examples:
- It’s a wide spectrum heterogeneous cancer group with indolent isolated small tumours at one end all the way across to extremely aggressive metastatic cases at the other end.
- It’s a cancer type that can be syndromically functional or non-functional to add to diagnostic and management challenges.
- It’s a cancer that can appear almost anywhere in the human body.
One of it’s less well-known traits is the ability to produce multiple primary tumours. Most people might be thinking of Multiple Endocrine Neoplasia at this point (a syndrome that predisposes the patient to multiple primary tumours in different organs). However, I also mean multi-focal (multicentric), i.e. more than one primary in the same organ. And that is the focus of this post in regards Small Intestine NETs where this is a common occurrence (one Swedish study put that at 40%).
This new study from Sweden has appeared twice in the last month, one giving a highly technical summary of the genome mapping to a small group of tumours. The other gives a higher-level summary.
The conclusion from this small study is astonishing in that it would appear multifocal primary NETs in the small intestine are capable of producing their own metastases. I personally don’t believe that changes anything in terms of therapy, but it does reinforce the need for a full check during surgery, something known in surgical terms as “running the bowel” which can be done for different reasons depending on the scenario but in cases of small intestine NETs is important as many of these cases can have multifocal tumours (multiple primaries).
See the abstract below:
Let’s start with the overview as that is what most of you will be looking for. There’s also some technical stuff in this overview but genome mapping is a highly technical subject not understood by many.
Concrete clinical question
“When we remove neuroendocrine tumors in the small intestine, we often find many tumors in the same place, which is unusual. No other cancer really looks like this,” says Erik Elias, an endocrine surgeon at Sahlgrenska University Hospital and a post-doctoral researcher at the University of Gothenburg. “The cancer is also unusual because known driver mutations are largely absent.”
“The result was both unambiguous and surprising. The intestinal tumors had developed independently. Yet the metastases were clearly related and could be traced back to a specific bowel tumor.”
Elias, E., Ardalan, A., Lindberg, M. et al. Independent somatic evolution underlies clustered neuroendocrine tumors in the human small intestine. Nat Commun 12, 6367 (2021). https://doi.org/10.1038/s41467-021-26581-5
Click this link to read full article:
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.
Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Top 10 Posts & Pages in the last 48 hours (auto updates) (Click the titles to read them)
Thanks for reading.
Sign up for my newsletters – Click Here
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for Digestive Neuroendocrine Carcinoma
This ENETS guidance paper, developed by a multidisciplinary working group, provides up-to-date and practical advice on the diagnosis and management of digestive neuroendocrine carcinoma, based
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastric neuroendocrine tumours (NETs) G1–G3
The ENETS 2023 guideline for gNETs are combined with the guidelines for Duodenal NET (dNET) due to their close relationship in anatomical terms. Gastric neuroendocrine
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for Duodenal neuroendocrine tumours (NETs) G1–G3
The ENETS 2023 guideline for dNETs are combined with the guidelines for Gastric NET (gNET) due to their close relationship in anatomical terms. But there
D Day I was 54 years and 9 months old at diagnosis on 26th July 2010. For the first few months, I had no idea
Another episode in the expert opinion series. I thought this might be useful for some of you after an interesting ‘google alert’ brought up these